Novo Nordisk lists Wegovy at $1,349 a month while selling the same pen self-pay for $349 — on its own website. Same company, same pen. Four myths about why, honestly sorted.
Structured with AI assistance and strictly fact-checked by our editorial team against primary sources. How we work →
Figures from Novo Nordisk's and Eli Lilly's own published prices, NovoCare's self-pay page, NICE's UK tariff, Denmark's official register, KFF coverage surveys, and CMS. Where a number is reported or still changing, we say so.
| Market | Figure | Context | Source |
|---|---|---|---|
| United States | $1,349/month (list) | Wegovy's US list price is $1,349.02/month (Novo Nordisk). But Novo sells the same pen self-pay for $349 on its own site (since Nov 2025; new patients $199 the first two months). Zepbound tells the same story: $1,086 list vs Lilly's own $299–449 cash vials. | Novo Nordisk pricing page · NovoCare · Lilly (2026) |
| Their own site | $349/month (self-pay) | The strangest gap here isn't between countries — it's on one company's own pages. $1,349 list versus $349 cash, same pen, same maker. Paying the cash price is still about $4,188 a year for one prescription. | NovoCare self-pay (Nov 2025) |
| Germany · UK · Denmark | ~€277 · £73–176 · ~$340 | The identical Wegovy pen runs about €277 in Germany (reported, post-Apr-2025 cut), £73–176 on the UK list plus a £9.90 NHS charge (NICE 2023), and about $340 in Denmark — Novo's home country. They negotiate one national price. | reported DE prices · NICE TA875 · medicinpriser.dk (2026) |
| The catch — coverage | Conditional | A Medicare pilot began July 1, 2026: $50 copay for weight-loss use — a first, but temporary (through end-2027); the negotiated $385 Wegovy price doesn't start until Jan 2027. In 2025 under half of large employers covered these drugs, and only 13 state Medicaid programs still did. | CMS pilot (2026) · KFF |
We compare what the drug costs, not what anyone should take, switch, or import. Treatment decisions belong with you and a licensed prescriber.
On July 1, 2026, a Medicare pilot began covering drugs like Wegovy and Zepbound for weight loss at a $50 copay — the first time Medicare has covered these drugs for weight loss at all. An honest comparison says that loudly. It also says the rest: the pilot is scheduled only through the end of 2027, the negotiated $385 Wegovy price doesn't begin until January 2027, and it does nothing for the employer-coverage gap, where fewer than half of America's largest employers covered these drugs in 2025 and only 13 state Medicaid programs still did as of January 2026 (KFF).
Novo Nordisk sells the same semaglutide pen two ways on its own pages: $1,349 list and $349 self-pay. Eli Lilly does the same with tirzepatide: $1,086 list versus $299–449 cash vials. When a company's own price list spans a four-fold range for the same drug, the list price is a choice, not a cost. Peer-reviewed estimates put manufacturing at $0.89–$4.73 a month (JAMA Network Open).
Personal importation isn't a legal right — regulators typically tolerate a 90-day personal supply at their discretion, and packages can be seized. The counterfeit problem is not hypothetical: fake semaglutide has turned up inside regulated pharmacies in the US, UK and Brazil (FDA and WHO alerts). And the cheap compounded workaround closed in 2025, when courts ended the shortage-era exception. Before paying list, the safe move is knowing every legitimate channel — the maker's own $349 cash page, the new Medicare pilot, and plan-by-plan coverage checks.
Wegovy's US list price is $1,349.02 a month (Novo Nordisk), but the same company sells it self-pay for $349 a month on its own NovoCare site — since November 2025, with new patients paying $199 for the first two months. Abroad, the identical pen runs about €277 in Germany (reported), £73–176 on the UK list (plus a £9.90 NHS charge), and about $340 in Denmark, Novo's home country. Same semaglutide, same maker.
The maker's own pricing suggests otherwise. Novo sells the same pen self-pay for $349, and Lilly sells cash-pay Zepbound vials for $299–449 — far under their ~$1,349 and ~$1,086 list prices. Peer-reviewed estimates put a sustainable, cost-based semaglutide price at $0.89–$4.73 a month (JAMA Network Open). The list price reflects the pricing system, not the chemistry.
Conditionally. On July 1, 2026 a Medicare pilot began covering weight-loss drugs at a $50 copay — the first time ever — but it's temporary (through the end of 2027), and the negotiated $385 Wegovy price doesn't start until January 2027. Outside Medicare, fewer than half of America's largest employers covered these drugs in 2025, and only 13 state Medicaid programs still did as of January 2026 (KFF).
No — it's the same semaglutide pen from the same manufacturer. The structural difference is that those countries negotiate a single national price; the US largely pays list. In 2023 data, Peterson-KFF found the US list price roughly 4.1× Germany's and 4.6× the Netherlands'.
It's rarely the clean shortcut it sounds like. Personally importing prescription drugs isn't a legal right — regulators typically exercise discretion for a 90-day personal supply, and packages can be seized. Counterfeit semaglutide has been found inside regulated pharmacies in the US, UK and Brazil (FDA/WHO), and courts closed the compounded-copy workaround in 2025. Before paying list, the safe move is knowing every legitimate channel — including the maker's own $349 cash page.
Directionally, yes. Novo's self-pay Wegovy price fell to $349 in November 2025, its list halves to $675 on January 1, 2027, Medicare-negotiated prices start the same day, and in April 2026 Canada approved the first G7 generic semaglutide. Presented strictly as cost data, not guidance — treatment decisions belong with a licensed prescriber.
Wellness Vision does not sell medication, book trips, or receive referrals of any kind. The data comes from the public sources cited above. This is a cost comparison, not medical advice — nothing here tells anyone to start, stop, switch, or import a medication.
📋 Or get the free Medical Travel Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
